VRNA (Verona Pharma) Days Payable : 404.94 (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Verona Pharma Days Payable?

Verona Pharma's average Accounts Payable for the three months ended in Dec. 2024 was $9.05 Mil. Verona Pharma's Cost of Goods Sold for the three months ended in Dec. 2024 was $2.04 Mil. Hence, Verona Pharma's Days Payable for the three months ended in Dec. 2024 was 404.94.

The historical rank and industry rank for Verona Pharma's Days Payable or its related term are showing as below:

VRNA' s Days Payable Range Over the Past 10 Years
Min: 859.26 Med: 3937.9 Max: 6832.67
Current: 859.26

During the past 13 years, Verona Pharma's highest Days Payable was 6832.67. The lowest was 859.26. And the median was 3937.90.

VRNA's Days Payable is ranked better than
83.93% of 703 companies
in the Biotechnology industry
Industry Median: 122.89 vs VRNA: 859.26

Verona Pharma's Days Payable increased from Dec. 2023 (0.00) to Dec. 2024 (404.94). It may suggest that Verona Pharma delayed paying its suppliers.

Verona Pharma Days Payable Historical Data

The historical data trend for Verona Pharma's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verona Pharma Days Payable Chart

Verona Pharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Days Payable

Get a 7-Day Free Trial

6,832.67

1,043.12

Verona Pharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Days Payable	Get a 7-Day Free Trial															-	-	-	922.83	404.94

Competitive Comparison of Verona Pharma's Days Payable

For the Biotechnology subindustry, Verona Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Verona Pharma's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verona Pharma's Days Payable distribution charts can be found below:

* The bar in red indicates where Verona Pharma's Days Payable falls into.

Save Embed

;

Save Embed

;

Verona Pharma Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Verona Pharma's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as

	Days Payable (A: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2023 )	+	Accounts Payable (A: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2024 )	*	Days in Period
=	( (3.492	+	11.266)	/	2 )	/	2.582	*	365
=	7.379					/	2.582	*	365
=	1,043.12

Verona Pharma's Days Payable for the quarter that ended in Dec. 2024 is calculated as:

	Days Payable (Q: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2024 )	+	Accounts Payable (Q: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
=	( (6.831	+	11.266)	/	2 )	/	2.039	*	365 / 4
=	9.0485					/	2.039	*	365 / 4
=	404.94

Verona Pharma Days Payable Related Terms

Thank you for viewing the detailed overview of Verona Pharma's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Verona Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verona Pharma PLC (NAS:VRNA) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

I9SA:Germany I9SA:Germany

Address

3 More London Riverside, London, GBR, SE1 2RE

Website

https://www.veronapharma.com

Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.

Executives

Kathleen A. Rickard	officer: Chief Medical Officer	C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE
Mark W Hahn	officer: Chief Financial Officer	6340 QUADRANGLE DRIVE, SUITE 100, CHAPEL HILL NC 27517
David Zaccardelli	director, officer: President and CEO	300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069
David R Ebsworth	director	C/O CURAGEN CORP, 555 LONG WHARF DR. 11TH FL., NEW HAVEN CT 06511
Christina Ackermann	director	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Martin Edwards	director	15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Claire Poll	officer: General Counsel	C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Rishi Gupta	director, 10 percent owner	C/O CHEMOCENTRYX, INC., 850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043
Access Industries Holdings Llc	10 percent owner	C/O ACCESS INDUSTRIES MANAGEMENT, LLC., 730 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10019
Ai Biotechnology Llc	10 percent owner	C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Access Industries Management, Llc	10 percent owner	730 FIFTH AVENUE, NEW YORK NY 10019
Len Blavatnik	10 percent owner	C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019
James Aloysius Brady	director	C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE
Lisa Deschamps	director	C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE